


Remarks

Claims 46-58 and 84-93 are pending at this time. Claims 47-50, 55-58 and 84-93 are rejected as lacking sufficient written description in the specification as filed. The Examiner has suggested that claims 49 and 84-93 be amended to recite that the peptide is bound to an MHC class II DR3 or DR4 allele selected from the group consisting of DR B1 0301, DR B1 0401, DR B1 0402, DR B1 0404 and peptide-binding fragments thereof. Applicants have amended herein claims 49 and 84-91 and now submit that the claims now fully comply with 35 U.S.C. §112, first paragraph. Applicants therefore request that the rejection be withdrawn.

Claim 57 is rejected on grounds of indefiniteness. In particular, the examiner objects to the phrase "accessory stimulating component." This claim has been amended to incorporate the limitations of claim 58 and claim 58 has been canceled. No new matter has been added. Applicants submit that this amendment overcomes that objection and that the rejection of claim 57 therefore should be withdrawn.

Applicants request reconsideration and allowance of the application at this time.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Martha Cassidy Reg. No. 44,066				
SIGNATURE				DATE	November 9, 2005
Address	Rothwell, Figg, Ernst & Manbeck 1425 K Street, N.W., Suite 800				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031